Top 10 drugs to watch
Published Updated
1 Min Read
For reprint and licensing requests for this article, click here.
More From Employee Benefit News
Benefits Think Moving to a top-down diagnostic of program value
A financial spreadsheet alone cannot capture the total value and performance of a benefits program, nor can numbers on a ledger guarantee long-term operational success.
Donovan Pyle
Health Compass Consulting
The compliance risks to watch out for this back-to-school season
Establishing policies that help with stressors like commuting logistics and finding after-school care can avoid disruption of in-office expectations.
Q&A: Aflac’s Matthew Owenby is watching burnout closely
The 2026 Excellence in Benefits winner is leading the insurance company's efforts to close the preventative care gap and personalize the employee experience.
Fewer women are being promoted to the top ranks, often lacking critical leadership support
The responsibility of bridging the career gap will fall predominantly on upper management and their support efforts.
Employers face a new GLP-1 question: Are the drugs worth it?
As GLP-1 spending climbs, employers are asking whether the drugs deliver enough value. Better data could help them measure the payoff more accurately.
